Imjudo
Imjudo ingredients
| Active ingredient | Strength |
|---|---|
| Tremelimumab | 300 mg/15mL, 25 mg/1.25mL |
What Imjudo is used for
The FDA lists the approved uses on the official label (below). In the EU, tremelimumab is approved as Imjudo for:
Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Imjudo
- Generic name
- Tremelimumab
- Made by
- AstraZeneca Pharmaceuticals LP
- Forms
- Injection, Solution
- Given
- Intravenous
- Drug class
- CTLA-4-directed Blocking Antibody
- FDA approval
- Biologic licence (BLA) BLA761289
- On the US market since
- 2022
Official information
- Imjudo prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Tremelimumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Imjudo?
Imjudo (Tremelimumab) is a cancer medicine made by AstraZeneca Pharmaceuticals LP, approved by the US FDA.
What are the ingredients of Imjudo?
Imjudo contains Tremelimumab (300 mg/15mL, 25 mg/1.25mL).
Is Imjudo approved in Europe?
The same active substance is approved in the EU as Imjudo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA